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Purpose of the study
Switch to once daily unboosted (u) atazanavir (ATV) is
an attractive option for HIV-infected patients with
undetectable viral load, due to its convenience and
favorable metabolic profile. However, due to a large
interindividual variability, increased risk of inadequate
ATV plasma concentrations (ATVc) and virological fail-
ure (VF) may be observed. Dividing the daily dose in a
t w i c ead a y( B I D )r e g i m e nc o u l di n c r e a s eA T V ca n d
improve virological success.
Methods
In a prospective observational cohort of HIV-infected
patients, all individuals with undetectable viral load who
were switched to uATV during at least one month were
retrospectively selected. ATVc were measured by a vali-
dated HPLC in all patients at least two weeks after the
initiation of ATV. ATVc was considered inadequate
when trough concentration was below 0,150 mg/L.
Patients with once (400 mg QD) versus twice daily (200
mg BID) uATV were compared.
Summary of results
From 2002 to 2009, 58 patients who received a total of
69 uATV based-regimens (27 QD and 42 BID regimens)
were included. At the start of uATV, patients received a
median duration of 9 years (IQR 4-11) of antiretroviral
therapy. The mean exposure time of uATV was 16
months. Clinical characteristics and comedications
(including tenofovir) were similar in the two groups.
ATVc was inadequate in 17 (63%) patients in the QD
group versus 4 (9%) patients in the BID group
(p<0.001). During the follow up, VF happened signifi-
cantly more frequently in the QD group than in the BID
group (6 [22%] versus 1 [2%]; p=0.012). VF or low
ATVc lead to treatment discontinuation in10 (37%) QD
regimens versus 4 (9%) BID regimens (p=0,06). No
other significant differences were detected in the two
groups.
Conclusions
Despite possible bias due to the observational study
design, strong differences were detected in plasma drug
exposure and virological outcome in our study. When a
switch to uATV is proposed in HIV-controlled patients,
BID would be preferred to QD.
Author details
1Hopital de la Croix Rousse, Service de Maladies Infectieuses et Tropicales,
Lyon, France.
2Hopital Edouard Herriot, Laboratoire de Pharmacologie, Lyon,
France.
3Hotel Dieu, Service d’hépato-gastro-entérologie, Lyon, France.
4Hopital Edouard Herriot, Service d’immunologie clinique, Lyon, France.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P47
Cite this article as: Baudry et al.: Switch to once or twice daily
unboosted atazanavir in a cohort of stable HIV patients: strong
differences in drug exposure and virological outcome. Journal of the
International AIDS Society 2010 13(Suppl 4):P47.
1Hopital de la Croix Rousse, Service de Maladies Infectieuses et Tropicales,
Lyon, France
Full list of author information is available at the end of the article
Baudry et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P47
http://www.jiasociety.org/content/13/S4/P47
© 2010 Baudry et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.